The Use of Protease Inhibitors in Pregnancy: Maternal and Fetal Considerations

Table 2

Markers of maternal disease status during pregnancy in HIV-infected women by type of antepartum antiretroviral therapy.

	ART with a protease inhibitor	ART without a protease inhibitor	No ART	value
Duration of diagnosis, years	2.0 0.5, 4.7	1.0 0.4, 2.7	0.2 0, 1.0		<0.001
Viral load, copies/mL
At presentation	2,054 37, 20,965	1,372 0, 12,266	4,770 643, 20,400	0.02
At delivery	0 0, 251	0 0, 1347	2,540 0, 25,940	<0.001
CD4 count, cells/mm^3
At presentation	463 299, 626	456 314, 624	557 375, 747	0.001
At delivery	524 372, 693	505 349, 677	565 337, 717	0.349

Data reported as median quartiles.